Novartis’ Afinitor Gets Expanded Indication as Pediatric Brain Tumor Treatment

Drug Industry Daily
A A
The FDA has approved Novartis’ Afinitor to treat a rare brain tumor called subependymal giant cell astrocytoma (SEGA) in children ages 1 and older, expanding its indication for the condition.

To View This Article:

Login

Subscribe To Drug Industry Daily